Zhiming Shao

53PUBLICATIONS
118CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (53)

|Aug 25, 2026
Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer.

|Aug 24, 2026
CHST1 Drives Immunotherapy Resistance in Triple-Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF-CCL20-Macrophage Axis.

|Aug 04, 2026
Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.

|Jun 18, 2026
Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.

|Apr 13, 2026
Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.

Yaxin Zhao, Han Wang, Ying Wang

|Mar 11, 2026
Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer.

Xiao-Hong Ding, Fenfang Chen, Fan Yang

Pageof 9

Frequent Collaborators

17 joint publications

Yi-Zhou Jiang

9 joint publications

Ding Ma

8 joint publications

Yi Xiao

5 joint publications

Wen-Tao Yang